GlassScriptPhysician profile
Sara Syeda
NPI 1962835439
$1,608.16
in general payments reported to CMS, 2019-2025
23 companies · $917 in 2025
The $917 reported for 2025 was more than what 76% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.03 · 2020: $78.99 · 2022: $36.30 · 2023: $108 · 2024: $409 · 2025: $917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,433.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $589.10 | 2024-2025 | Krystexxa, Tavneos |
| Travere Therapeutics, INC. | $126.14 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $108.97 | 2020-2025 | Farxiga, Lokelma |
| Horizon Therapeutics Plc | $88.33 | 2019-2023 | Krystexxa |
| Veloxis Pharmaceuticals, INC. | $73.63 | 2025 | Envarsus |
| Mallinckrodt Hospital Products INC. | $67.41 | 2025 | Terlivaz, Acthar |
| Boston Scientific Corporation | $61.84 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $50.42 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $46.58 | 2024-2025 | Jynarque |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $46.06 | 2025 | |
| Calliditas Therapeutics US INC. | $40.67 | 2025 | Tarpeyo |
| Novo Nordisk INC | $37.95 | 2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $35.80 | 2025 | |
| Recor Medical INC | $32.16 | 2024-2025 | Paradise Renal Denervation System, Paradise Ultrasound Renal Denervation System |
| Genzyme Corporation | $24.80 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $24.63 | 2019 | |
| Apellis Pharmaceuticals, INC. | $24.29 | 2025 | |
| Amicus Therapeutics, INC. | $24.20 | 2023 | Galafold |
| Vifor Pharma, INC. | $24.12 | 2025 | Veltassa |
| Takeda Pharmaceuticals U.S.A., INC. | $21.75 | 2025 | Livtencity |
| Genentech USA, INC. | $21.74 | 2025 | Gazyva |
| Glaxosmithkline, LLC. | $19.64 | 2025 | Shingrix, Arexvy |
| Opko Pharmaceuticals, LLC | $17.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Syeda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.